The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms.
We investigated the coregulator (coactivator and corepressor) interactions with the mineralocorticoid receptor (MR) that lead to activation and inhibition of the receptor in the presence of agonist and/or antagonist. Our results indicate that MR ligand binding domain (LBD) interacts strongly with only a few specific coactivator peptides in the presence of the agonist aldosterone and that these interactions are blocked by the antagonist eplerenone. We also discovered that cortisol, the preferred physiological ligand for the glucocorticoid receptor in humans, is a partial MR agonist/antagonist, providing a possible molecular explanation of the tissue-selective effects of glucocorticoids on MR. However, when we examined the coactivator and corepressor peptide interactions in the presence of cortisol, we found that MR bound with cortisol or aldosterone interacted with the same set of peptides. Thus, the partial agonism shown by cortisol is unlikely to be the result of differential interaction with known coactivators and corepressors. On the other hand, we have identified coactivator binding groove mutations that are critical for cortisol activation but not for aldosterone activation, suggesting that the two steroids induce different MR LBD conformations. In addition, we also show that cortisol becomes full agonist when S810L mutation is introduced in the LBD of MR. Interestingly, MR antagonists, such as eplerenone and progesterone, become partial agonist/antagonist of S810L but are still able to recruit LXXLL peptides to the mutant receptor. Together, these findings suggest a model to explain the MR activation by various ligands.
Hultman
Monica L
ML
St. Louis Laboratories, Biological Sciences, Pfizer Global Research & Development, Missouri 63017, USA.
Krasnoperova
Nataliia V
NV
Li
Suzhen
S
Du
Sarah
S
Xia
Chunsheng
C
Dietz
Jessica D
JD
Lala
Deepak S
DS
Welsch
Dean J
DJ
Hu
Xiao
X
D000450:Aldosterone / Q000378:metabolism; D020816:Amino Acid Motifs; D000595:Amino Acid Sequence; D002460:Cell Line; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D000077545:Eplerenone; D031541:Fluorescence Resonance Energy Transfer; D005786:Gene Expression Regulation; D005938:Glucocorticoids / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000737:chemistry / Q000378:metabolism; D008024:Ligands; D008954:Models, Biological; D008969:Molecular Sequence Data; D009154:Mutation; D010455:Peptides / Q000737:chemistry; D011485:Protein Binding; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D018161:Receptors, Mineralocorticoid / Q000378:metabolism*; D017386:Sequence Homology, Amino Acid; D013148:Spironolactone / Q000031:analogs & derivatives / Q000737:chemistry; D014158:Transcription, Genetic; D014162:Transfection
D005938:Glucocorticoids; D008024:Ligands; D010455:Peptides; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone; D000450:Aldosterone; D000077545:Eplerenone; D006854:Hydrocortisone